Ludwig Institute for Cancer Research, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; Department of Oncology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Ludwig Institute for Cancer Research, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Lancet Oncol. 2019 Aug;20(8):e417-e433. doi: 10.1016/S1470-2045(19)30401-2. Epub 2019 Jul 29.
Except for its use in palliative care, radiotherapy has been largely abandoned in the management of ovarian cancer because of the recognised efficacy and lower toxicity of systemic chemotherapy compared with radiotherapy. New data have emerged that show synergy of radiotherapy with immunotherapy to control or eradicate cancer. Different doses of hypofractionated radiotherapy have been shown to induce immunogenic cell death and in-situ vaccination in several tumour models. However, doses less than 2 Gy can also reprogramme the tumour microenvironment. This Series paper discusses the past and present use of radiotherapy for ovarian cancer, and the mechanisms by which radiotherapy can mobilise anticancer immunity. We provide emerging preclinical and clinical data for combining immunotherapy with radiotherapy for ovarian cancer treatment and offer a clinical development roadmap to guide the next generation of clinical trials for this combination strategy for this disease.
除姑息治疗外，由于与放疗相比，系统化疗具有更好的疗效和更低的毒性，放疗在卵巢癌治疗中的应用已基本被放弃。新出现的数据表明，放疗与免疫疗法具有协同作用，可以控制或消除癌症。多项肿瘤模型研究表明，不同剂量的超分割放疗可诱导免疫原性细胞死亡和原位疫苗接种。然而，小于 2Gy 的剂量也可重新编程肿瘤微环境。本系列论文讨论了放疗在卵巢癌中的过去和现在的应用，以及放疗调动抗癌免疫的机制。我们提供了新兴的临床前和临床数据，用于将免疫疗法与放疗相结合治疗卵巢癌，并提供了一个临床开发路线图，以指导这一联合策略在该疾病的下一代临床试验。
